All In MedTech

FDA Clearance Tracker · P210016

ManaFuse

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Jan 17, 2025 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jan 17, 2025

Approved (reclassified)

Time to decision

1,362 days

Received Apr 26, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class II

The decision

FDA number
P210016
Device name
ManaFuse
Applicant
Enovis
Applicant location
Calrsbadd, NV
Received
Apr 26, 2021
Decided
Jan 17, 2025
Decision
Approved (reclassified)

Device type

Device class
Class II
Regulation
21 CFR 890.5870

Every decision under product code LOF

FDA's approval statement

As written in FDA's record.

The ManaFuse system is indicated for the non-invasive treatment of established non-unions excluding skull and vertebra, and for accelerating the time to a healed fracture for fresh, closed, posteriorly displaced distal radius fractures and fresh, closed or Grade I open tibial diaphysis fractures in skeletally mature adult individuals when these fractures are orthopedically managed by closed reduction and cast immobilization.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LOF. The earliest in FDA's data is P790002, decided Nov 6, 1979.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Enovis

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.